Sad News: Professor Martin Gore

BOPA was saddened to learn of the untimely passing of Professor Martin Gore, from The Royal Marsden whom many of you will have seen delivering the Plenary Session at last Octobers BOPA Symposium.   We work in a speciality that teaches us life can be short, but that never makes it easier when a colleague passes.  Prof Martin Gore was a friend to BOPA, many of our exec committee over the years worked with him and benefitted from his excellence, wisdom and humour.  I only briefly knew Martin from working with him on the Chemotherapy CRG, but what a pleasure to have had the chance to learn from a truly inspiring person.  One of the joys of working as an oncology pharmacist is the people we work with, so thank you, Martin, for being a friend to BOPA and our heartfelt condolences to his family, friends and colleagues at this awful time.
 

Latest News

By BOPA Research Committee on 25th April 2024

Survey: Pharmacogenomic Panel Testing in Cancer: UK Oncology Professionals

Please consider completing our BOPA member survey on the use of pharmacogenomic panel testing in people with solid tumours. Survey information I’m a pharmacist and pre-doctoral research fellow researching the…

Read article
By BOPA Research committee on 25th April 2024

NIHR Associate Principal Investigator (PI) Scheme is continuing to host Research Learning Lectures

The NIHR Associate Principal Investigator (PI) Scheme is continuing to host the Research Learning Lectures; a series of lectures for anyone in Health and Social Care interested in learning more about research.…

Read article
By BOPA on 16th April 2024

Abstract Submission for #BOPA2024 is NOW OPEN

Abstract Submission for the 27th Annual BOPA Conference in 2024 is now OPEN   Delegates are invited to present results of their clinical and technical work as a poster with…

Read article
By BOPA Research Subcommittee on 15th April 2024

Survey: Service Evaluation on Carboplatin Variation in UK

We invite members to complete this service evaluation to understand national variations in carboplatin dosing for adult patients receiving SACTs. We are looking at whether we can standardise carboplatin protocols…

Read article